Conference
Abstract C17: A phase I study of the combination of RO4929097 (RO) and cediranib (Cd) in patients with advanced solid tumors (PJC-004/NCI 8503).
Abstract
Abstract
Background: The NOTCH signaling pathway has been implicated in the tumorigenesis of several human cancers. Pre-clinical models have shown that deficiency of components of the NOTCH pathway results in abnormal vascular remodelling. Upregulation of NOTCH signaling has been implicated in resistance to anti-VEGF therapy, providing a rationale for the combination of RO, a gamma secretase inhibitor that disrupts NOTCH …
Authors
Castonguay V; Bedard PL; Chen HX; Ivy P; Oza AM; Chen EX; Hirte HW; McGarrity A; Laughlin A; Lovell S
Volume
10
Pagination
pp. c17-c17
Publisher
American Association for Cancer Research (AACR)
Publication Date
November 12, 2011
DOI
10.1158/1535-7163.targ-11-c17
Conference proceedings
Molecular Cancer Therapeutics
Issue
11_Supplement
ISSN
1535-7163